

October 9, 2024

Harris' In-Home Care, Vision, Hearing Aid Medicare Coverage Proposal – Likely an Undelivered Promise

We are skeptical of enactment for Vice President Kamala Harris' <u>campaign proposal</u> to add a Medicare in-home care benefit, along with vision and hearing aid coverage, even if she were to win (our base case) in a Democratic sweep (*not* our base case). While the idea is likely to be welcomed by **non-skilled home-care providers**, **eyeglass** and **hearing aid manufacturers**, and prescribers, the costs augur against success, as has been the case previously.

- Costs. The Brookings Institution posits that adding in-home, non-skilled personal care to Medicare, which would be available to certain enrollees with sliding-scale for cost sharing, would cost a total of \$40B/10 years, but this does not seem to include the potential labor wage increases and higher training costs to find qualified staff. While there is no current estimate for the limited vision and hearing aid coverage in Medicare, the Congressional Budget Office (CBO) found that ultimately abandoned 2019 proposals would have cost \$119B/10 years, or \$30B and \$89B, respectively.
- Offsets. Moreover, Harris' listed pay-fors, such as expanded government drug price negotiations and PBM reforms, will likely be needed to offset other higher cost / higher priority items like extension of the enhanced Obamacare subsidies that expire at the end of 2025 and Medicare physician payment reforms.
- Opposition. We would also expect to see opposition from Medicare Advantage plans that currently offer these benefits due to the competition it would imply, as well long-term care providers [e.g., nursing homes, skilled home health agencies] that are already suffering from insufficient staff and would be competing for the same labor personnel.
- Process. Finding the votes will also be difficult, as it is unclear to us whether the budget reconciliation process allowing for Senate passage with a simple majority could be used, given that a Medicare benefit expansion is not explicitly budgetary in nature. While Democrats had sought to include Medicare vision, hearing aid, and dental coverage in the 2019 Build Back Better plan, the effort was pulled before a parliamentary review took place, leaving the procedural path forward an open question.

Beth Steindecker

202-935-0946

beth.steindecker@capitolpolicypartners.com

(ADUS) Price:	\$129.02
52-Week High:	\$136.12
52-Week Low:	\$78.35
ModivCare Inc (MOI	OV)
Price:	\$16.16
52-Week High:	\$52.33
52-Week Low:	\$11.00
Inc. Common Stock	•
Price:	\$15.01
Price: 52-Week High:	\$15.01 \$15.47
Price:	\$15.01 \$15.47
Price: 52-Week High:	\$15.01 \$15.47 \$7.85
Price: 52-Week High: 52-Week Low:	\$15.01 \$15.47 \$7.85
Price: 52-Week High: 52-Week Low: Amedisys Inc (AMED	\$15.01 \$15.47 \$7.85))
Price: 52-Week High: 52-Week Low: Amedisys Inc (AMED	\$15.01 \$15.47 \$7.85 9) \$96.29 \$98.95
Price: 52-Week High: 52-Week Low: Amedisys Inc (AMED Price: 52-Week High:	\$15.01 \$15.47 \$7.85 9) \$96.29 \$98.95 \$89.55
Price: 52-Week High: 52-Week Low: Amedisys Inc (AMED Price: 52-Week High: 52-Week Low:	\$15.01 \$15.47 \$7.85 9) \$96.29 \$98.95 \$89.55
Price: 52-Week High: 52-Week Low: Amedisys Inc (AMED Price: 52-Week High: 52-Week Low: Sonova H Ag (SOON)	\$15.01 \$15.47 \$7.85)) \$96.29 \$98.95 \$89.55



DISCLOSURES AND DISCLAIMERS

Analyst Certification

The analyst, Capitol Policy Partners, primarily responsible for the preparation of this research report attests to the following: (1) that the views and opinions rendered in this research report reflect his or her personal views about the subject companies or issuers; and (2) that no part of the research analyst's compensation was, is, or will be directly related to the specific recommendations or views in this research report.

Analyst Certifications and Independence of Research.

Each of the Capitol Policy Partners analysts whose names appear on the front page of this report hereby certify that all the views expressed in this Report accurately reflect our personal views about any and all of the subject securities or issuers and that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views of in this Report. Capitol Policy Partners (the "Company") is an independent equity research provider. The Company is not a member of the FINRA or the SIPC and is not a registered broker dealer or investment adviser. Capitol Policy Partners has no other regulated or unregulated business activities which conflict with its provision of independent research.

Limitation Of Research And Information.

This Report has been prepared for distribution to only qualified institutional or professional clients of Capitol Policy Partners. The contents of this Report represent the views, opinions, and analyses of its authors. The information contained herein does not constitute financial, legal, tax or any other advice. All third-party data presented herein were obtained from publicly available sources which are believed to be reliable; however, the Company makes no warranty, express or implied, concerning the accuracy or completeness of such information. In no event shall the Company be responsible or liable for the correctness of, or update to, any such material or for any damage or lost opportunities resulting from use of this data. Nothing contained in this Report or any distribution by the Company should be construed as any offer to sell, or any solicitation of an offer to buy, any security or investment. Any research or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of an overall portfolio strategy and you should consult with a professional financial advisor, legal and tax advisor prior to making any investment decision. Capitol Policy Partners shall not be liable for any direct or indirect, incidental or consequential loss or damage (including loss of profits, revenue or goodwill) arising from any investment decisions based on information or research obtained from Capitol Policy Partners.

Reproduction And Distribution Strictly Prohibited.

No user of this Report may reproduce, modify, copy, distribute, sell, resell, transmit, transfer, license, assign or publish the Report itself or any information contained therein. Notwithstanding the foregoing, clients with access to working models are permitted to alter or modify the information contained therein, provided that it is solely for such client's own use. This Report is not intended to be available or distributed for any purpose that would be deemed unlawful or otherwise prohibited by any local, state, national or international laws or regulations or would otherwise subject the Company to registration or regulation of any kind within such jurisdiction.

Copyrights, Trademarks, Intellectual Property.

Capitol Policy Partners, and any logos or marks included in this Report are proprietary materials. The use of such terms and logos and marks without the express written consent of Capitol Policy Partners is strictly prohibited. The copyright in the pages or in the screens of the Report, and in the information and material therein, is proprietary material owned by Capitol Policy Partners unless otherwise indicated. The unauthorized use of any material on this Report may violate numerous statutes, regulations and laws, including, but not limited to, copyright, trademark, trade secret or patent laws.